Medicine · 2018 · 31 citations · 33 references
MedicineOncologySurgeryEndocrine OncologyMetastasisSurgical OncologyCervical Lymph Node MetastasisLymph Node MetastasisLymph Node PathologyNeck DissectionThyroid CancerThyroid SurgeryCervical Lymph Node DissectionLymph Node MetastasesPapillary Thyroid Carcinoma PathologyPartial ThyroidectomyTherapeutic Lateral Neck DissectionThyroid Cancer LymphadenectomyThyroid Cancer PathologyThyroid Carcinoma Metastasis To Lymph Nodes
The surgical extension of lateral neck dissection (LND) in papillary thyroid carcinoma (PTC) with clinical lateral lymph node metastases (LLNM) remains controversial. The aim of this study was to explore the pattern of and clinicopathologic risk factors for LLNM in PTC with clinical unilateral LND to determine the rational extent of therapeutic LND.This retrospective study reviewed the records of 246 consecutive patients with PTC who simultaneously underwent total thyroidectomy, bilateral central lymph node dissection, and unilateral therapeutic LND. The frequency and pattern of LLNM were analyzed.Grossly, LLNM were present in 80.9% of patients, and level II to V lymph node metastases (LNM) were present in 45.9%, 62.6%, 56.1%, and 11.8% patients, respectively. Superior tumor location, extrathyroidal extension, and ipsilateral, contralateral, and bilateral central LNM (CLNM) were independent risk factors for gross LLNM. Age ≥45 years, superior lobe tumors, extrathyroidal extension, and ipsilateral and contralateral CLNM were independent risk factors for level II LNM. Age ≥45 years, superior and middle lobe tumors, extrathyroidal extension, and ipsilateral CLNM were independent risk factors for level III LNM. Superior lobe tumors and ipsilateral, contralateral, and bilateral CLNM were independent risk factors for level IV LNM. Only contralateral CLNM was an independent risk factor for level V LNM.In PTC patients with clinical LLNM, the predominant sites of LLNM were levels II to IV and not level V. Therapeutic elective LND should include the lateral nodal levels associated with independent risk factors, especially superior tumors location and CLNM.
33
Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy
Jacqueline Jonklaas, Nicholas J. Sarlis, Danielle R. Litofsky et al. · Thyroid · 2006 · 694 citations
Clinically significant prognostic factors for differentiated thyroid carcinoma
Catharina Ihre Lundgren, Per Hall, Paul W. Dickman et al. · Cancer · 2005 · 658 citations · Full text